Use of DNA repair proteins translated from biomarker screening to predict overall survival in patients with esophageal cancer treated with oxaliplatin chemotherapy
Sharma RA. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Juric D. et al, (2012), CANCER RESEARCH, 72
Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate.
Khan OA. et al, (2012), Br J Cancer, 106
Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
Khan OA. et al, (2012), British Journal of Cancer, 106
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
Patterson DM. et al, (2012), Clin Cancer Res, 18, 1415 - 1425
Pulmonary nodules in patients with melanoma--assume nothing.
Murphy F. et al, (2012), Ann Oncol, 23, 545 - 546
Tumor refractoriness to anti-VEGF therapy is mediated by myeloid cell recruitment in malignant melanoma
Helfrich I. et al, (2012), EXPERIMENTAL DERMATOLOGY, 21, e45 - e45
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
Gillies RS. et al, (2012), Br J Surg, 99, 239 - 245
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
Dean E. et al, (2012), Br J Cancer, 106, 468 - 474
New challenges in endpoints for drug development in advanced melanoma.
Ribas A. et al, (2012), Clin Cancer Res, 18, 336 - 341
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM. et al, (2012), Clin Cancer Res, 18, 555 - 567
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Leijen S. et al, (2011), Cancer Chemother Pharmacol, 68, 1619 - 1628
Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.
Sabharwal A. et al, (2011), Melanoma Res, 21, 502 - 508
Periampullary Cancer ESPAC-3(v2) trial: a Randomised Controlled Phase III Trial of Adjuvant Chemotherapy Versus Observation in Patients With Periampullary Adenocarcinomas of the Head of the Pancreas
Neoptolemos J. et al, (2011), PANCREAS, 40, 1343 - 1343
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer (vol 104, pg 1822, 2011)
Khan OA. et al, (2011), BRITISH JOURNAL OF CANCER, 105, 1252 - 1252
Erratum: Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer (British Journal of Cancer (2011) 104 (1822-1827) DOI:10.1038/bjc.2011.154)
Khan OA. et al, (2011), British Journal of Cancer, 105
Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience
Rughani MG. et al, (2011), Journal of Plastic, Reconstructive and Aesthetic Surgery, 64, 1284 - 1290
Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience.
Rughani MG. et al, (2011), J Plast Reconstr Aesthet Surg, 64, 1284 - 1290
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Mitchell CL. et al, (2011), Cancer Chemother Pharmacol, 68, 631 - 641
Efficacy of Veliparib (ABT-888) Plus Temozolomide Versus Temozolomide Alone: a Randomized, Double-blind, Placebo-controlled Trial in Patients with Metastatic Melanoma
Middleton M. et al, (2011), EUROPEAN JOURNAL OF CANCER, 47, 8 - 8